Cresco Labs (CRLBF) Capital Leases (2023 - 2026)

Cresco Labs (CRLBF) posted Capital Leases of $17.6 million for Q1 2026, down 3.91% on a QoQ basis from $18.3 million in Q4 2025.

Cresco Labs (CRLBF) Capital Leases (2023 - 2026) Analysis & Trends

Cresco Labs' Capital Leases history runs 3 years deep, the most recent figure standing at $17.6 million for Q1 2026.

  • Quarterly Capital Leases changed N/A year-over-year to $17.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.6 million (changed N/A YoY) and the FY2025 annual result came in at $18.3 million, changed N/A from the prior year.
  • Capital Leases was $17.6 million for Q1 2026 at Cresco Labs, down from $18.3 million in the prior quarter.
  • Across five years, Capital Leases topped out at $22.4 million in Q4 2023 and bottomed at $17.6 million in Q1 2026.
  • A 3-year average of $19.4 million and a median of $18.3 million in 2025 frame the typical range for Capital Leases.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Haleon 89.28 Bn 87.42 Bn -
2 Teva Pharmaceutical Industries 35.97 Bn 32.23 Bn 1.97 Bn
3 Zoetis 32.42 Bn 30.48 Bn 1.62 Bn
4 Takeda Pharmaceutical 27.48 Bn 23.42 Bn 4.39 Bn
5 United Therapeutics 22.89 Bn 20.73 Bn 648.10 Mn
6 RedHill Biopharma 22.11 Bn 22.11 Bn -
7 Viatris 20.44 Bn 18.64 Bn 1.16 Bn
8 Neurocrine Biosciences 17.76 Bn 16.44 Bn 800.70 Mn
9 Elanco Animal Health 12.62 Bn 12.19 Bn 785.00 Mn
10 Cresco Labs 245.85 Mn 182.28 Mn 75.45 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 17.56 Mn
Dec 31, 2025 18.27 Mn
Dec 31, 2023 22.38 Mn